药物相互作用致环孢素不良反应分析及药学监护

常馨予; 郭桂明; 刘洋; 韩丽娟; 车晓平; 范峥; 常馨予; 郭桂明; 刘洋; 韩丽娟; 车晓平; 范峥

doi:10.3969/j.issn.1006-0111.2018.04.018

[1]

兰瑛. 环孢素A与抗结核药物合用患者的药学监护[J]. 中国药师, 2015,18(2):268-270.

[2]

XIAOYAN PANG, YIFAN ZHANG, RUINA GAO, et al. Effects of rifampin and ketoconazole on pharmacokinetics of morinidazole in healthy Chinese subjects[J].Antimicrob Agents Chemother. 2014 Oct, 58(10):5987-5993.

[3]

WEN XI, WANG JS, NEUVONEN PJ, et al. Isoniazid is a mechanism-based inhibitor of cytochrome P4501A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes[J]. Eur J Clin Pharmacol,2002, 57(11):799-804.

[4]

LIU ZW, HU ZH, CAI YY. The combined effect of isoniazid and rifampicin on the activities of CYP4501A2 and CYP4503A4 in primary hepatocytes from healthy human adults[J]. Zhonghua Jiehe he Huxi Zazhi,2005, 28(11):785-788.

[5]

程凯, 贾萍, 徐埏, 等. 72例环孢素A所致不良反应文献分析[J]. 中国药业, 2010, 19(1):36-37.

[6]

DA SILVA JB, DE MELO LIMA MH, SECOLI SR. Influence of cyclosporine on the occurrence of nephrotoxicity after allogeneic hematopoietic stem cell transplantation:a systematic review[J]. Rev Bras Hematol Hemoter, 2014, 36(5):363-368.

[7]

曲彩红, 苏向阳. 伏立康唑致环孢素血药浓度升高相关癫痫样发作[J]. 药物不良反应杂志, 2010, 12(5):354-356.

[8]

毕晓莹. 环抱霉素的神经系统毒性[J]. 国外医学神经病学神经外科学分册, 2004, 31(6):519-522.

[9]

YANAGIMACHI M, NARUTO T, TANOSHIMA R, et al. Influence of CYP3A5 and ABCB1 gene polymorphisms on calcineurin inhibitor-related neurotoxicity after hematopoietic stem cell transplantation[J]. Clin Transplant 2010:24:855-861.

[10]

CRETTOL S, VENETZ JM, AUBERT J, et al. CYP2A7, CYP3A5, CYP3A4, and ABCB1 genetic polymorphisms, cyclosporine concentration, and dose requirement intransplant recipients[J]. Ther Drug Monit, 2008, 30(6):689-699.

[11]

丁伶清, 田雪梅, 王彦娥, 等. 环孢素A药动学/药效学/不良反应的影响因素分析[J]. 中国医院药学杂志, 2016, 36(21):1935-1939.

[12]

WANG YI, WANG C, LI J, et al. Effect of genetic polymorphisms of CYP3A5 and MDR1 on cyclosporine concentration during the early stage after renal transplantation in Chinese patients co-treated with diltiazem[J]. Eur J Clin Pharmacol. 2009 Mar; 65(3):239-247.

[13]

GROUP AW. Kidney disease:Improving global outcomes(KDIGO).KDIGO clinical practice guidelines for anemia in chronic kidney disease[J]. Kidney International,2012:279-335.

[14]

马丽,林冰,王丽英,等. 预防治疗系统性红斑狼疮患者医源性活动性结核病的临床观察[J]. 中华医学杂志,2014,94(45):3579-3582.

[15]

WILLIAMSON B, DOOLEY KE, ZHANG Y,et al. Induction of influx and efflux transporters and cytochrome P4503A4 in primary human hepatocytes by rifampin, rifabutin, and rifapentine[J]. Antimicrob Agents Chemother,2013,57(12):6366-6369.

[16]

BOLHUIS MS, PANDAY PN, PRANGER AD, et al. Pharmacokinetic drug interactions of antimicrobial drugs:A systematic review on oxazolidinones, rifamycines, macrolides, fluoroquinolones, and beta-lactams[J]. Pharmaceutics,2011,3(4):865-913.